291 related articles for article (PubMed ID: 23999236)
1. DNA damage response (DDR) induced by topoisomerase II poisons requires nuclear function of the small GTPase Rac.
Wartlick F; Bopp A; Henninger C; Fritz G
Biochim Biophys Acta; 2013 Dec; 1833(12):3093-3103. PubMed ID: 23999236
[TBL] [Abstract][Full Text] [Related]
2. Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons.
Huelsenbeck SC; Schorr A; Roos WP; Huelsenbeck J; Henninger C; Kaina B; Fritz G
J Biol Chem; 2012 Nov; 287(46):38590-9. PubMed ID: 23012366
[TBL] [Abstract][Full Text] [Related]
3. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
Turner JG; Marchion DC; Dawson JL; Emmons MF; Hazlehurst LA; Washausen P; Sullivan DM
Cancer Res; 2009 Sep; 69(17):6899-905. PubMed ID: 19690141
[TBL] [Abstract][Full Text] [Related]
4. Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha.
Bau JT; Kurz EU
Biochem Pharmacol; 2011 Feb; 81(3):345-54. PubMed ID: 20959117
[TBL] [Abstract][Full Text] [Related]
5. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.
Deng S; Yan T; Nikolova T; Fuhrmann D; Nemecek A; Gödtel-Armbrust U; Kaina B; Wojnowski L
Br J Pharmacol; 2015 May; 172(9):2246-57. PubMed ID: 25521189
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase poisons differentially activate DNA damage checkpoints through ataxia-telangiectasia mutated-dependent and -independent mechanisms.
Siu WY; Lau A; Arooz T; Chow JP; Ho HT; Poon RY
Mol Cancer Ther; 2004 May; 3(5):621-32. PubMed ID: 15141020
[TBL] [Abstract][Full Text] [Related]
7. Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide.
Drummond CJ; Finlay GJ; Broome L; Marshall ES; Richardson E; Baguley BC
Invest New Drugs; 2011 Oct; 29(5):1102-10. PubMed ID: 20567995
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
Aoyama M; Grabowski DR; Dubyak GR; Constantinou AI; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Biochem J; 1998 Dec; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
[TBL] [Abstract][Full Text] [Related]
9. Phenolic-containing organic extracts of mulberry (Morus alba L.) leaves inhibit HepG2 hepatoma cells through G2/M phase arrest, induction of apoptosis, and inhibition of topoisomerase IIα activity.
Naowaratwattana W; De-Eknamkul W; De Mejia EG
J Med Food; 2010 Oct; 13(5):1045-56. PubMed ID: 20828312
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of topoisomerase IIα and induction of DNA damage in cholangiocarcinoma cells by altholactone and its halogenated benzoate derivatives.
Kitdumrongthum S; Reabroi S; Suksen K; Tuchinda P; Munyoo B; Mahalapbutr P; Rungrotmongkol T; Ounjai P; Chairoungdua A
Biomed Pharmacother; 2020 Jul; 127():110149. PubMed ID: 32344256
[TBL] [Abstract][Full Text] [Related]
11. Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.
Kumar A; Ehrenshaft M; Tokar EJ; Mason RP; Sinha BK
Biochim Biophys Acta; 2016 Jul; 1860(7):1519-27. PubMed ID: 27095671
[TBL] [Abstract][Full Text] [Related]
12. Structural determinants of the catalytic inhibition of human topoisomerase IIα by salicylate analogs and salicylate-based drugs.
Bau JT; Kurz EU
Biochem Pharmacol; 2014 Jun; 89(4):464-76. PubMed ID: 24695359
[TBL] [Abstract][Full Text] [Related]
13. Salicylate, a catalytic inhibitor of topoisomerase II, inhibits DNA cleavage and is selective for the α isoform.
Bau JT; Kang Z; Austin CA; Kurz EU
Mol Pharmacol; 2014 Feb; 85(2):198-207. PubMed ID: 24220011
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of prostate smooth muscle contraction and prostate stromal cell growth by the inhibitors of Rac, NSC23766 and EHT1864.
Wang Y; Kunit T; Ciotkowska A; Rutz B; Schreiber A; Strittmatter F; Waidelich R; Liu C; Stief CG; Gratzke C; Hennenberg M
Br J Pharmacol; 2015 Jun; 172(11):2905-17. PubMed ID: 25631101
[TBL] [Abstract][Full Text] [Related]
15. Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis.
Kurose A; Tanaka T; Huang X; Halicka HD; Traganos F; Dai W; Darzynkiewicz Z
Cytometry A; 2005 Nov; 68(1):1-9. PubMed ID: 16184611
[TBL] [Abstract][Full Text] [Related]
16. Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIalpha and beta in various human cancer cell lines.
Hochhauser D; Valkov NI; Gump JL; Wei I; O'Hare C; Hartley J; Fan J; Bertino JR; Banerjee D; Sullivan DM
J Cell Biochem; 1999 Nov; 75(2):245-57. PubMed ID: 10502297
[TBL] [Abstract][Full Text] [Related]
17. Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening.
Drwal MN; Marinello J; Manzo SG; Wakelin LP; Capranico G; Griffith R
PLoS One; 2014; 9(12):e114904. PubMed ID: 25489853
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials.
Guo L; Liu X; Nishikawa K; Plunkett W
Mol Cancer Ther; 2007 May; 6(5):1501-8. PubMed ID: 17513599
[TBL] [Abstract][Full Text] [Related]
19. QS-ZYX-1-61 induces apoptosis through topoisomerase II in human non-small-cell lung cancer A549 cells.
Chen MC; Pan SL; Shi Q; Xiao Z; Lee KH; Li TK; Teng CM
Cancer Sci; 2012 Jan; 103(1):80-7. PubMed ID: 21920000
[TBL] [Abstract][Full Text] [Related]
20. Sodium salicylate acts through direct inhibition of phosphoinositide 3-kinase-like kinases to modulate topoisomerase-mediated DNA damage responses.
Fan JR; Huang TH; Wen CY; Shen TL; Li TK
Eur J Pharmacol; 2010 Jul; 638(1-3):13-20. PubMed ID: 20406630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
